Apeloa Pharmaceutical announced it has appointed multiple new members to its Scientific Advisory Board, as the body convened its second session in Hengdian last month.
The Apeloa Scientific Advisory Board (ASAB) convened to discuss strategies to strengthen Apeloa’s R&D and global competitiveness going forward, by boosting technological development, innovation and international collaborations.
Key board appointments included internationally renowned scientist Prof. Shengming Ma from Fudan University, who was also named ASAB Chairman. In addition, Prof. Yuguo Zheng from Zhejiang University of Technology and Prof. Phil S. Baran from Scripps Research also joined as board members, bringing more world-class scientific talent to Apeloa.
Apeloa’s Chairman Brian Zhu welcomed the ASAB members to the board and presented them with certificates. Brian spoke about the role of ASAB in guiding strategy, informing technical decisions, and providing valuable scientific insights. During the meeting, members made a number of key recommendations to strengthen Apeloa’s position in the global market.
Members stressed the importance of collaboration with academic and research institutions. Partnerships in academia and research can help Apeloa stay at the forefront of new technologies, gain strength crucial fields and improve its visibility in the scientific community.
The meeting highlighted the value of sustainability in pharmaceutical innovation, including for AI-driven technologies in the chemical industry. These recommendations closely align with Apeloa’s own strategy, which plans to focus on high-value fine chemicals and explore new approaches like electrochemistry and photochemistry, to meet demand for sustainable and high-quality products.
Earlier in the day, Apeloa Pharmaceutical hosted its 7th “Doctor’s Club” meeting, convening over 70 Ph.D. staff and executives from Apeloa as well as various other science experts from around the world. Through speeches and interactions, they explored academic research, industry practice and managerial insights.
Prof. Phil S. Baran presented a lecture focusing on innovative approaches in organic chemistry. He urged greater imagination in designing new chemical reactions, rather than only sticking to traditional methods, to help find simpler, more efficient ways to carry out chemical reactions.
For Apeloa, these ideas inspired new and innovative ways to streamline drug development. By adopting shorter reaction paths and simpler conditions, Apeloa can improve the efficiency of organic synthesis and reduce costs, thus speeding up new drug production. The approach also applauds more creativity in research teams, to help break through conventions in chemical research.
Through ASAB discussions and “Doctor’s Club” presentations, Apeloa demonstrates commitment to fostering a collaborative environment for scientific exchange and technological innovation. The company’s R&D efforts will continue to benefit from global expertise, contributing to a more sustainable future and healthcare innovation.
